Search results
AstraZeneca Buy rating, stock target reiterated on consistent presence By Investing.com
Investing.com· 18 hours agoOn Wednesday, Citi reaffirmed its Buy rating on AstraZeneca (NASDAQ:AZN) shares with a steady price...
AstraZeneca completes Fusion Pharmaceuticals acquisition
Pharmaceutical Technology via Yahoo Finance· 1 day agoAstraZeneca has announced the conclusion of its acquisition of clinical-stage biopharmaceutical...
AstraZeneca completes acquisition of biopharma company Fusion Pharma
dpa international via Yahoo Finance· 1 day agoBritish pharmaceutical company AstraZeneca on Wednesday announced the completion of the acquisition...
This Pharma Stock Is Poised to Keep Outperforming the S&P 500
Motley Fool via Yahoo Finance· 7 days agoAstraZeneca has quietly delivered market-beating results since 2014. Despite skepticism, the company...
Deutsche Bank maintains 'Hold' on AstraZeneca post ASCO conference By Investing.com
Investing.com· 21 hours agoOn Monday, Deutsche Bank reiterated a Hold rating and a price target of GBP110.00 on stock of ...
Why CEO AstraZeneca believes the drugmaker can almost double revenue by 2030
CNBC· 1 day agoAstraZeneca CEO Pascal Soriot explained in a Tuesday interview with CNBC's Jim Cramer why the...
Summit Therapeutics, AstraZeneca And More From The Year’s Biggest Cancer Conference
Forbes· 10 hours agoThe American Society of Clinical Oncology held its annual conference in Chicago this past week,...
Data Science Hiring Process at AstraZeneca
Analytics India Magazine· 21 hours agoWith over 45 years of presence in India, British-Swedish pharmaceutical and biotechnology giant AstraZeneca has data science and AI capabilities deeply ingrained across its ...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 14 hours agoThe Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding (MoU) with AstraZeneca during BIO International ...
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 6 days agoAstraZeneca’s longest-serving chief executive, Pascal Soriot, has no plans to step down for now as...